37 results about "Pet tracer" patented technology

The invention provides a PET tracer precursor compound as well as a preparation method and application thereof, and also discloses a < 68 > Ga-labeled PET tracer, the PET tracer precursor compound is simple in preparation method, short in preparation time and high in radiochemical yield, and has the advantages of good in-vivo and in-vitro stability, high specificity, high intake and the like; the tumor or inflammation part can be accurately and stably detected and positioned; the Ga-68 labeled targeted PARP-1 radioactive probe synthesized on the basis of the compound Olaparib can realize qualitative diagnosis of PARP-1 in tumors, further realizes non-invasive accurate quantification of PARP-1 in tumors, provides a reliable basis in stages of clinical staging, treatment decision, curative effect monitoring and the like, and finally realizes accurate diagnosis and treatment.

The invention provides a PET tracer precursor compound of a targeted CDK4 / 6 receptor and a preparation method and application of the PET tracer precursor compound, and further discloses a < 68 > Ga-labeled PET tracer. The PET tracer precursor compound is simple in preparation method, short in preparation time, high in radiochemical yield and suitable for industrial production. And the probe has the advantages of good in-vivo and in-vitro stability, high specificity, high intake and the like, and can be used for accurately and stably detecting and positioning tumor or inflammation parts. Besides, the PET tracer is a Ga-68-labeled targeted CDK4 / 6 radioactive probe synthesized on the basis of a compound Palbociclib, qualitative diagnosis of CDK4 / 6 in tumors can be achieved, then noninvasive accurate quantification of CDK4 / 6 in tumors is achieved, a reliable basis is provided in the stages of clinical staging, treatment decision making, curative effect monitoring and the like, and finally accurate diagnosis and treatment are achieved.

The present invention provides radiolabeled GABAA γ1 positive allosteric modulators (PAM) that are useful for medical imaging.

The invention discloses a compound targeting AT1R, which is composed of a target head molecule targeting AT1R, a PEG linker, an aspartic acid linker and a chelating agent, and can be used as a component of a PET tracer agent targeting AT1R. A target head molecule can be embedded into a hydrophobic'pocket 'of AT1R protein, so that high-affinity and high-selectivity targeted binding is realized; the PEG connexon can prolong the residence time of the PET tracer agent targeting the AT1R at the tumor part; different numbers of aspartic acids can regulate and control the pharmacokinetic properties of the PET tracer agent targeting the AT1R, reduce the liver and gall and intestinal signal backgrounds of the PET tracer agent targeting the AT1R, and improve the target-to-cost ratio. Therefore, accurate diagnosis and treatment of digestive system diseases such as digestive tract tumor and liver cancer can be realized. The invention further discloses a PET tracer agent targeting AT1R as well as a preparation method and application of the PET tracer agent.

Disclosed herein is a PET tracer compound (S)-1-(2-(6-[18F]fluoropyridin-3-yl)-4-(trifluoromethyl)phenyl)-N-(pyrimidin-2-yl)-2,3-dihydro-1H-indene-5-sulfonamide and salts thereof, and uses of the same as imaging agents. Also disclosed are precursor compounds, such as (S)-1-(2-(6-nitropyridin-3-yl)-4-(trifluoromethyl)phenyl)-N-(pyrimidin-2-yl)-2,3-dihydro-1H-indene-5-sulfonamide, and salts thereof. Also disclosed are kits comprising the same.

The invention discloses a method for rapidly measuring the pH value of a trace PET probe through a spectrum method and application of the method. The method has the advantages that the using amount of a sample is extremely small, a standard spectrum curve is drawn after experimental conditions are optimized, the measuring steps are simple, the measuring result is high in accuracy and sensitivity, and meanwhile microfluidic automatic online measuring can be achieved. The PET tracer agent has the characteristics of small synthesis amount, high price, radioactivity and the like, so that the PET tracer agent has huge application value in the aspects of testing the use amount of samples, simplifying detection, realizing automatic testing and the like.

A system and method for simultaneous imaging of multiple positron emission tomography (PET) tracers in which digital data including PET information associated with at least two time points is received, where the digital data is generated by PET scans of a region of interest of a physiologic body which has been administered at least two PET tracers that differ from one another at least in their radioactive decay constant. At least one set of output digital data is determined based on the radioactive decay constants of each PET tracer, the at least one set of output digital data corresponding to at least one of the at least two PET tracers. The determination of at least one set of output digital data includes at least one of regularizing to account for statistical noise, preconditioning the digital data to be more amenable to signal separation, applying feature preservation techniques, or accounting for late tracer kinetics.

The invention relates to a CEACAM6 targeting nuclide ligand, a PET probe and a preparation method and application of the CEACAM6 targeting nuclide ligand, the CEACAM6 targeting nuclide ligand is obtained by modifying a targeting molecule through a bifunctional chelating agent, the targeting molecule is a nuclide aptamer, an antibody or polypeptide capable of targeting CEACAM6, and the targeting molecule is preferably Glu-Trp-Gln-Arg-Leu-Lys-Trp-Phe-Asp-His or Gly-Arg-Gln-Tyr-Asp-Tyr-Grp-Gln-Gly. CEACAM6 can be used as an appropriate target spot for PET-based noninvasive diagnosis of malignant pulmonary nodules in the early stage of LUAD. According to the present invention, the good PET probe is obtained by radiolabeling the nuclide ligand targeting CEACAM6; wherein the PET probes 68Ga-NODA-P2 and 68Ga-NODA-P3 capable of noninvasively and specifically targeting CEACAM6 can be used as potential PET tracers for accurately diagnosing the early lung malignant nodules of LUAD, misdiagnosis and excessive treatment caused by the malignant risk that the nodules cannot be accurately evaluated by virtue of LDCT screening are avoided, and particularly, the 68Ga-NODA-P3 probe shows the high-specificity imaging capability in a CEACAM6 positive A549 xenotransplantation tumor model, so that the CEACAM6 positive A549 xenotransplantation tumor model has the advantages that the CEACAM6 positive A549 xenotransplantation tumor model has the high-specificity imaging capability, and the CEACAM6 positive A549 xenotransplantation tumor model has the high-specificity imaging capability; according to the present invention, the CEACAM6 positive tumor and the CEACAM6 negative tumor can be significantly distinguished, the imaging target is high, the metabolism clearance is rapid, the rapid imaging diagnosis is easily achieved, and the accurate identification of the LUAD early stage malignant pulmonary nodule is easily achieved.

A radiosynthesis system is disclosed that leverages droplet microfluidic radiosynthesis and its inherent advantages including reduction of reagent consumption and the ability to achieve high molar activity even when using low starting radioactivity. The radiosynthesis system enables the parallel synthesis of radiolabeled compounds using droplet-sized reaction volumes. In some embodiments, a single heater is used to create multiple reaction or synthesis sites. In other embodiments, separate heaters are used to create independently-controlled heating conditions at the multiple reaction or synthesis sites. In one embodiment, a four-heater setup was developed that utilizes a multi-reaction microfluidic chip and was assessed for the suitability with high-throughput radiosynthesis optimization. Replicates of several radiochemical operations including the full synthesis of various PET tracers revealed the platform to have high repeatability (e.g., consistent fluorination efficiency). The system may also be used for synthesis optimization.

Using deep learning, imaging harmonization among images produced with differing PET tracers is achieved. A method may include providing an original PET image of the brain using an original PET tracer, providing a target PET tracer, and converting, using a deep learning neural network, the original PET image into a target PET image simulating the image that would be obtained had the target PET tracer been used.

Recombinant proteins that specifically bind TGFβ are disclosed. The recombinant proteins include a transforming growth factor beta (TGFβ) binding domain and an antibody Fc fragment. Also disclosed are compositions that include the disclosed recombinant protein, and methods of using such compositions for detecting TGFβ in a subject.

The invention provides a novel PET (Polyethylene Terephthalate) tracer agent of a targeted cannabinoid type 2 receptor and a preparation method of the novel PET tracer agent.

Disclosed herein is a PET tracer compound (S)-1-(2-(6-[18F]fluoropyridin-3-yl)-4-(trifluoromethyl)phenyl)-N-(pyrimidin-2-yl)-2,3-dihydro-1H-indene-5-sulfonamide and salts thereof, and uses of the same as imaging agents. Also disclosed are precursor compounds, such as (S)-1-(2-(6-nitropyridin-3-yl)-4-(trifluoromethyl)phenyl)-N-(pyrimidin-2-yl)-2,3-dihydro-1H-indene-5-sulfonamide, and salts thereof. Also disclosed are kits comprising the same.

The present application provides a radiolabeled compound targeting cannabinoid receptor type 1 with radionuclide 18F. The present application also provides a method for preparing the compound and its use as a positron emission tomography (PET) imaging agent.

The invention relates to application of 18F-FAPI-42 in preparation of a product for diagnosing lung lymphangioleiomyomatosis, and belongs to the technical field of radiography imaging agents. The invention discloses an application of < 18 > F-FAPI-42 in preparation of a product for diagnosing lung lymphangioleiomyomatosis. FAPI is a novel PET tracer agent, PET / CT of FAPI has the advantages of being low in radiation exposure, fast in-vivo metabolism and free of influences of blood glucose level changes, and patient tolerance is better. Compared with 68Ga, the radioactive isotope 18F has a longer half-life period and higher electron energy, and has more advantages in clinical use. As a novel PET / CT tracer, the 18F-FAPI-42 is remarkably superior to a traditional tracer 18F-FDG in the aspects of evaluating the condition of an LAM patient and identifying the focus of the LAM patient, including renal vascular smooth muscle lipoma, mediastinal lymphatic vessel myoma, abdominal lymphatic vessel myoma and pelvic lymphatic vessel myoma.

The application discloses a PET tracer targeting carbonic anhydrase IX (CA IX) and a preparation method and application thereof. 68 The tracer is prepared from a DOTA-bis-sulfonamide precursor compound and GaCl3 reaction. The tracer has high hydrophilicity, excellent stability in vitro and in vivo, low uptake of non-target organs and is mainly excreted through the kidney. Micro-PET / CT imaging shows that the tumor uptake is linearly correlated with the CA IX protein expression level measured by immunohistochemistry. Acute toxicity experiments show that the tracer has good biological safety. The application further provides a radiopharmaceutical composition containing the tracer and application of the tracer in preparation of a PET imaging agent for diagnosing CA IX positive tumors. The tracer has the advantages of high labeling efficiency, low background interference, accurate quantification and potential integration of diagnosis and treatment, and is suitable for precise molecular imaging of CA IX high expression tumors such as clear cell renal cell carcinoma and colorectal cancer.

There is provided two angiogenesis clinical PET tracers, namely 68Ga-NODAGA-E[c(RGDyK)]2 and 64Cu-NODAGA-E[c(RGDyK)]2 for imaging of neo-angiogenesis in humans.

The invention relates to the technical field of biological medicines, discloses a PET (Polyethylene Terephthalate) tracer for targeting tumor integrin alpha5beta1 as well as a labeled precursor, a preparation method and application of the PET tracer, and belongs to the technical field of biological medicines. The PEG tracer agent is of an F-X-R-G structure, X is a chelating agent, R is a connecting arm, G is a polypeptide compound, the amino acid sequence of the polypeptide compound is KSSPHSN (SG) 5RGDSP, KSSPHSN (SG) 5RGDSPC or KSSPHSN (SG) 5RGDSPC-PEG4, and F is selected from 64Cu. Experimental verification shows that the prepared PET tracer has good in-vivo stability, good binding specificity with tumor alpha5beta1, long tumor residence time and easy synthesis. The PEG tracer prepared by the invention has an important value in clinical application in polypeptide targeted nuclear drug tumor diagnosis and treatment integration.

The present application provides a PET tracer targeting cannabinoid receptor type 2 and a preparation method and application thereof.

The present invention relates to a device that allows to fully automate radiochemical purity analysis of radiolabelled solution samples on the basis of a chromatogram obtained by Thin Layer Chromatography (TLC), said device comprising a disposable TLC strip holder assembly, a radioactivity detector and an automatic equipment containing a pipettor.

The present invention relates to a device that allows for fully automated radiochemical purity analysis of radiolabeled solution samples based on chromatograms obtained by thin layer chromatography (TLC), said device comprising a disposable TLC strip holder assembly, a radioactivity detector and an automated device containing a pipettor.

There is provided two angiogenesis clinical PET tracers, namely 68Ga-NODAGA-E[c(RGDyK)]2 and 64Cu-NODAGA-E[c(RGDyK)]2 for imaging of neo-angiogenesis in humans.

Embodiments of the present disclosure provide compositions and methods for performing positron emission tomography (PET) and, more particularly, to compositions and methods for the development and use of 18F-based PET tracers for use in selected imaging techniques such as studies of agents selected to modulate adipose tissue physiology.

The present invention relates to new and inventive compounds of formula (I). The compounds are useful as PET (positron emission tomography) tracer.

The application belongs to the technical field of biological medicine, and particularly relates to design, synthesis and application of a tumor-targeting polypeptide tracer. The structure of the tumor-targeting polypeptide tracer comprises a tumor-targeting polypeptide (targeting vascular endothelial growth factor receptor 2 of tumor cells), a linker and a radionuclide chelating group. The polypeptide tracer provided by the application is modified by methionine at different sites to form a thioether bridge cyclic peptide, so that the tumor targeting ability, membrane penetration performance and in-vivo drug metabolism of the targeting polypeptide are improved, high concentration enrichment and long-time retention in the tumor tissue site can be realized, the targeting of the PET tracer is improved, and a more accurate and safer tumor tracer is realized.

The invention discloses a PET (Polyethylene Terephthalate) tracer targeting mGluR5. The PET tracer comprises a pyridine ring and a substituted benzene ring, a No.1 carbon atom of the substituted benzene ring is connected with a No.6 carbon atom of the pyridine ring through ethynyl, a No.2 carbon atom of the pyridine ring is connected with-CH3, and a No.3 carbon atom on the substituted benzene ring is connected with-OSO218F; substituent groups R1 are connected to a No.1 nitrogen atom, a No.3 carbon atom, a No.4 carbon atom and a No.5 carbon atom of a pyridine ring, substituent groups R2 are connected to a No.2 carbon atom, a No.4 carbon atom, a No.5 carbon atom and a No.6 carbon atom of a substituted benzene ring, and R1 is selected from a hydrogen atom, a cyano group, a halogen atom, a short-chain alkyl group, a short-chain alkoxy group, a hydroxyl group and a hydroxymethyl group; r2 is selected from a hydrogen atom, a cyano group, a halogen atom, a short-chain alkyl group and a short-chain alkoxy group. The PET tracer agent targeting mGluR5 provided by the invention has high specific binding capacity, and can realize accurate positioning and quantitative analysis of mGluR5 in a living body. The invention further discloses a preparation method and application of the PET tracer agent targeting mGluR5.

Embodiments of the invention disclosed herein provide methods for using certain18F-based PET tracers in selected imaging techniques including studies of T cell localization and function that is associated with systemic immunity. Embodiments of the invention include methods that use multiple PET tracers selected for their ability to observe certain regions in the subject in which the tracers accumulate and then determining a ratio of the signal intensity observed in the region with the first tracer with the signal intensity observed in the region in second tracer as a way to characterize systemic immunity. The methods disclosed herein that allow the quantification of T cell function in relation to tumor burden are useful in patient selection and therapy guidance, both of which are expected to dramatically increase success of immunotherapies and improve patients' clinical outcome.

The invention discloses application of a Ga-labeled peritoneal fibrosis marker PET tracer agent in peritoneal dialysis related peritoneal fibrosis diagnosis products, and belongs to the technical field of peritoneal function detection. According to the method, fibroblast activating protein, a discoid structural domain receptor 2, integrin linked kinase and the like are selected as peritoneal fibrosis markers, and gallium 68 is used for marking, so that the PET tracer is prepared. The tracer agent can be specifically combined to peritoneal fibrosis tissue, and PET imaging with high sensitivity and high specificity is achieved. Meanwhile, the invention also provides a corresponding PET diagnostic kit which integrates a tracer agent, a purified buffer solution, a stabilizer and image analysis software, so that the operation process is simplified, and the detection efficiency is improved. By means of the method, noninvasive and accurate detection of peritoneal fibrosis can be achieved, a scientific basis is provided for selection and adjustment of peritoneal dialysis schemes, the progress condition of peritoneal fibrosis can be continuously monitored, a treatment scheme can be adjusted in time, the dialysis time of peritoneal dialysis patients is expected to be prolonged, and the life quality is improved.

Two angiogenic clinical PET tracers, 68Ga-NODAGA-E[c(RGDyK)]2 and 64Cu-NODAGA-E[c(RGDyK)]2, are presented for imaging neovascularization in humans.